Clinical manifestations and visual outcomes associated with ocular toxoplasmosis in a Brazilian population.
Adolescent
Adult
Age Factors
Aged
Antibodies, Protozoan
/ blood
Antiprotozoal Agents
/ therapeutic use
Blindness
/ drug therapy
Brazil
Female
Humans
Immunoglobulin G
/ blood
Immunoglobulin M
/ blood
Male
Middle Aged
Pyrimethamine
/ therapeutic use
Recurrence
Retina
/ drug effects
Risk Factors
Sulfadiazine
/ therapeutic use
Toxoplasma
/ drug effects
Toxoplasmosis
/ drug therapy
Treatment Outcome
Trimethoprim, Sulfamethoxazole Drug Combination
/ therapeutic use
Uveitis, Posterior
/ drug therapy
Vision, Ocular
/ drug effects
Visual Acuity
/ drug effects
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 02 2021
04 02 2021
Historique:
received:
21
09
2020
accepted:
21
01
2021
entrez:
5
2
2021
pubmed:
6
2
2021
medline:
16
11
2021
Statut:
epublish
Résumé
Ocular toxoplasmosis is the leading cause of posterior uveitis worldwide. We conducted an observational study of 262 consecutive individuals (n = 344 eyes) with ocular toxoplasmosis who were followed over a 34-month period. Most subjects were T. gondii IgG + /IgM- (n = 242; 92.4%; 317 eyes), and 140 eyes (40.7%) had active lesions. For eyes in which retinal lesions were active at recruitment and best-corrected visual acuity (BCVA) could be measured (n = 133), 21.0% (n = 28) remained blind (BCVA below 20/400) after inflammation resolved. In these eyes, atypical ocular toxoplasmosis (OR 4.99; 95% CI 1.14-22.85; p = 0.0330), macular lesion (OR 9.95; 95% CI 2.45-47.15; p = 0.0019) and any complication (OR 10.26; 95% CI 3.82-30.67; p < 0.0001) were associated with BCVA below 20/200. For eyes with only inactive lesions at recruitment and BCVA measured (n = 178), 28.1% (n = 50) were blind. In these eyes, having at least one lesion larger than one disc-diameter (OR 6.30; 95% CI 2.28-22.46; p = 0.0013) and macular lesion (OR 5.69; 95% CI 2.53-13.54; p < 0.0001) were associated with BCVA below 20/200. Older age (OR 1.02; 95% CI 1.00-1.05; p = 0.0493) and active disease at presentation (OR 4.74; 95% CI 1.95-12.91; p = 0.0011) were associated with recurrences. Additional clinical attention should be directed towards patients with risk factors for poor visual outcome.
Identifiants
pubmed: 33542439
doi: 10.1038/s41598-021-82830-z
pii: 10.1038/s41598-021-82830-z
pmc: PMC7862362
doi:
Substances chimiques
Antibodies, Protozoan
0
Antiprotozoal Agents
0
Immunoglobulin G
0
Immunoglobulin M
0
Sulfadiazine
0N7609K889
Trimethoprim, Sulfamethoxazole Drug Combination
8064-90-2
Pyrimethamine
Z3614QOX8W
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3137Références
Am J Ophthalmol. 2004 Jan;137(1):1-17
pubmed: 14700638
Surv Ophthalmol. 2012 Mar-Apr;57(2):149-77
pubmed: 22137039
Am J Ophthalmol. 2014 Apr;157(4):762-766.e1
pubmed: 24388839
Am J Ophthalmol. 2002 Jul;134(1):41-6
pubmed: 12095806
Am J Ophthalmol. 2008 Jun;145(6):1007-1013
pubmed: 18343351
Ocul Immunol Inflamm. 2011 Aug;19(4):262-6
pubmed: 21770804
Clin Exp Ophthalmol. 2013 Jan-Feb;41(1):82-94
pubmed: 22594908
Clin Microbiol Rev. 2012 Apr;25(2):264-96
pubmed: 22491772
PLoS Negl Trop Dis. 2016 May 02;10(5):e0004685
pubmed: 27136081
Ocul Immunol Inflamm. 2017 Jun;25(3):382-387
pubmed: 26914347
Ophthalmology. 2002 May;109(5):869-78
pubmed: 11986090
Am J Ophthalmol. 2016 Oct;170:176-182
pubmed: 27521607
Clin Exp Ophthalmol. 2013 Jan-Feb;41(1):95-108
pubmed: 22712598
Ocul Immunol Inflamm. 2019;27(5):722-730
pubmed: 29953310
Am J Ophthalmol. 2020 May;213:195-202
pubmed: 31926883
Ocul Immunol Inflamm. 2018;26(2):317-323
pubmed: 27598330
Parasitology. 2012 Sep;139(11):1375-424
pubmed: 22776427